Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $382000.0.

  • Amicus Therapeutics' Capital Expenditures rose 730.34% to $382000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year decrease of 3424.74%. This contributed to the annual value of $3.6 million for FY2024, which is 5224.46% down from last year.
  • Latest data reveals that Amicus Therapeutics reported Capital Expenditures of $382000.0 as of Q3 2025, which was up 730.34% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Capital Expenditures ranged from a high of $2.7 million in Q4 2022 and a low of -$137000.0 during Q3 2022
  • In the last 5 years, Amicus Therapeutics' Capital Expenditures had a median value of $890000.0 in 2021 and averaged $1.1 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 11539.33% in 2022, then soared by 124233.58% in 2023.
  • Quarter analysis of 5 years shows Amicus Therapeutics' Capital Expenditures stood at $1.8 million in 2021, then surged by 52.1% to $2.7 million in 2022, then tumbled by 35.34% to $1.7 million in 2023, then crashed by 83.36% to $288000.0 in 2024, then skyrocketed by 32.64% to $382000.0 in 2025.
  • Its Capital Expenditures was $382000.0 in Q3 2025, compared to $2.4 million in Q2 2025 and $212000.0 in Q1 2025.